Skip to main content
. Author manuscript; available in PMC: 2024 Jan 7.
Published in final edited form as: Cancer Discov. 2023 Jul 7;13(7):1656–1677. doi: 10.1158/2159-8290.CD-22-0601

Figure 4. MFN2 overexpression reduces sensitivity of AML cells to BH3-mimetics.

Figure 4.

a. Immunoblotting in lysates from MOLM-13 cells adenovirally transduced with MFN2 (Ad-MFN2) or scramble control.

b-c. Annexin V staining in MOLM-13 (b) or Kasumi-1 (c) cells ectopically expressing MFN2 and subsequently treated with MCL1i (AMG176) for 24 hrs (n=3, mean ± SEM). Statistics were calculated using one-way ANOVA.

d. Dose-response curves of Ven+Aza from Kasumi-1 cells ectopically overexpressing MFN2 or control vector.

e. Annexin V assays of Kasumi-1 cells transduced with control or MFN2-targeting sgRNAs, followed by overexpressing vector control or indicated MFN2 constructs. Cells were treated with 500 nM AMG176 for 24 hrs before staining for Annexin V and DAPI.

f. Bar graphs depicting the frequencies of alive mitophagic cells in mitoKeima-expressing MOLM-13 cells transduced with MFN2 (Ad-MFN2) or scramble control treated with 1 μM MCL1i (AMG176) for 16 hrs (n=3, mean ± SD).

g. Annexin V staining in MOLM-13 cells ectopically expressing MFN2, after treatment with 500 nM AMG176 and 200 nM ULK1i for 24 hrs (n=3, mean ± SD). Statistics were calculated using two-way ANOVA.